Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.

Affiliation

Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: [Email]

Abstract

Indatuximab ravtansine (BT062) is an antibody-drug conjugate that binds to CD138, which is overexpressed on multiple myeloma (MM) cells.

Keywords

Antibody-drug conjugate,CD138,Monoclonal antibody,Multiple-dose,Syndecan-1,

OUR Recent Articles